Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Global Forecasts To 2017

News provided by

Apr 25, 2013, 01:45 ET

NEW YORK, April 25, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Global Forecasts To 2017

http://www.reportlinker.com/p01165168/Drug-Delivery-Technologies-Market-Metered-Dose-Inhalers-Needle-Free-Injectors-Auto-Injectors-Nasal-Sprays-Transdermal-Patches-Nebulizers-Infusion-Pumps-Drug-Eluting-Stents-Sustained-Release-Ocular-Implants---Global-Forecasts-To-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

The drug delivery technology market is segmented on the basis of route of administration into nine categories - oral, pulmonary, transdermal, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery; the market is forecast till 2017. Over the years, drug delivery technologies have grown phenomenally from plain drug reformulation and release technologies to innovative platforms that hold a huge potential for the effective delivery of biologicals and novel drugs.

The global drug delivery market was worth $142.5 billion in the year 2012. Patent expiries of certain blockbuster drugs, growing demand for self administration and home healthcare devices, rising incidence of chronic diseases such as cardiovascular diseases, diabetes and cancer, growing focus on pediatric and geriatric patients, and advancing technology are accelerating the growth of this market. However, drug failures and recalls, and technical barriers will hamper the growth of this market, to a certain extent.

Strategic collaborations, self administration and home care drug delivery devices, and expanding applications of drug delivery into niche therapeutic areas represent vast opportunities for key players in this market. The growing number of elderly persons is a large consumer of home care drug delivery devices. The global ageing population (above 60 years) is set to increase from 784 million in 2011 to 2 billion by 2050 and 2.8 billion by 2100. (Source: UN Population Division). An increase in the number of geriatric patients and rise in demand for convenient drug delivery options pose major opportunities for the development of innovative and easy-to-use drug delivery systems.

Striking right partnership deal and enhancing the bioavailability of drugs are some of the burning issues in this market. In spite of a large number of strategic collaborations taking place every year, pharmaceutical and biotechnology companies are facing problems in finding a right drug delivery partner. Considering this need, a number of national and international conferences are organized by various associations and organizations to facilitate drug delivery partnerships.

The geographies covered in this study are North America, Europe, Asia and Rest of the world (RoW). North America is the largest market for drug delivery, followed by Europe and Asia. North America and Europe are expected to grow at a slower pace, primarily due to a certain amount of saturation in the market. The Asian market is poised to register maximum growth over the next five years, owing to the expansion of Asian economy, increase in disposable income, development of healthcare infrastructure, increasing penetration of health insurance, and rising prevalence of chronic diseases.

Scope of the Report

This research report categorizes the global drug delivery market into oral, pulmonary, transdermal, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. These markets are broken down into segments and sub-segments, providing exhaustive value analysis for 2010, 2011 and 2012, as well as forecast up to 2017. Each of the drug delivery market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.

Global drug delivery market, by route of administration

Oral
Controlled Release
Orodispersible Tablets (ODT) and Taste Masking
Others

Pulmonary
Dry Powder Inhalers
Metered Dose Inhalers
Nebulizers
Transdermal
Passive
Reservoir System
Matrix System
Active
Iontophoresis
Microporation
Others

Injectable
Conventional Injection Devices
Fillable Syringes
Prefilled Syringes
Self-injection Devices
Needle-free Injectors
Auto-injectors or Safety Syringe Devices
Pen Injectors
Others

Ocular
Eye Drops
Ointment and Gel
Others
Nasal
Nasal Drops
Nasal Sprays
Nasal Inhalers
Others

Topical
Liquid Formulations
Semi-solid Formulations
Solid Formulations
Implantable
Drug Eluting Stents
Implantable Infusion Pumps
Intravitreal Implants
Brachytherapy Seeds
Contraceptive Implants
Transmucosal
Oral (Buccal and Sublingual)
Others (Rectal and Vaginal)

Geographic analysis

North America
Europe
Asia
Rest of the World (RoW)

TABLE OF CONTENTS

1 INTRODUCTION 23
1.1 KEY TAKE-AWAYS 23
1.2 REPORT DESCRIPTION 23
1.3 MARKETS COVERED 25
1.4 STAKEHOLDERS 26
1.5 RESEARCH METHODOLOGY 27
1.5.1 MARKET SIZE 27
1.5.2 MARKET SHARE 27
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 28
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES 28
1.5.5 ASSUMPTIONS 28

2 EXECUTIVE SUMMARY 29

3 MARKET OVERVIEW 34

3.1 INTRODUCTION 35
3.2 MARKET SEGMENTATION 35
3.3 MARKET DYNAMICS 37
3.3.1 DRIVERS 37
3.3.1.1 Patent cliff and increased competition to increase adoption rate 37
3.3.1.2 Improving patient compliance and acceptability, an impetus to the drug delivery systems market 38
3.3.1.3 Increasing focus on pediatric and geriatric patients to boost the growth 39
3.3.1.4 Increasing incidence of chronic diseases to enhance demand 39
3.3.2 RESTRAINTS 40
3.3.2.1 Drug failures and recalls mar market growth 40
3.3.2.2 Technical barriers restrict growth 41
3.3.3 OPPORTUNITIES 42
3.3.3.1 Collaborations between pharmaceutical companies and drug delivery firms 42
3.3.3.2 Self-administration and home care drug delivery devices 42
3.3.3.3 Expanding therapeutic applications of drug delivery technologies 43
3.3.4 TARGETED DRUG DELIVERY 44
3.3.4.1 Passive systems contribute 60% to the targeted drug delivery market 44
3.3.4.2 Active targeted drug delivery has major applications in cancer therapy 44
3.3.4.3 Companies focus on novel targeted drug delivery 45
3.3.5 BURNING ISSUES 45
3.3.5.1 Striking right partnerships 45
3.3.5.2 Improving the bioavailability of drugs 46
3.4 REGULATORY ENVIRONMENT 47
3.4.1 STRINGENT REGULATIONS FOR PHARMACEUTICAL DRUGS ACROSS THE GLOBE 47
3.4.1.1 The approval process is complex, time-consuming, and expensive 47
3.4.2 EFFECT OF THE U.S. HEALTHCARE REFORMS ON THE DRUG DELIVERY INDUSTRY 48
3.4.3 REGULATIONS RELATED TO THE APPROVAL OF CONTROLLED RELEASE DRUGS 48
3.5 PORTER'S FIVE FORCES ANALYSIS 49
3.6 VALUE CHAIN ANALYSIS 51
3.7 MARKET SHARE ANALYSIS 52
3.7.1 PULMONARY DRUG DELIVERY 52
3.7.2 TRANSDERMAL DRUG DELIVERY 54
3.7.3 INJECTABLE DRUG DELIVERY 55
3.7.3.1 Conventional injection devices 55
3.7.3.2 Self-injection devices 56
3.7.4 IMPLANTABLE DRUG DELIVERY 58
3.7.5 OTHER DRUG DELIVERY SEGMENTS 59

4 GLOBAL DRUG DELIVERY MARKET, BY TECHNOLOGY 61

4.1 INTRODUCTION 62
4.1.1 DRUG DELIVERY MARKET WITNESSING TECHNOLOGICAL ADVANCEMENTS 62
4.2 OPPORTUNITY MATRIX 63
4.3 ORAL DRUG DELIVERY 64
4.3.1 BIG PHARMA COMPANIES ESTABLISHING IN-HOUSE CAPABILITIES 65
4.3.2 CONTROLLED RELEASE 68
4.3.3 ORODISPERSIBLE TABLETS (ODT) AND TASTE MASKING 70
4.3.4 OTHERS 71
4.4 PULMONARY DRUG DELIVERY 73
4.4.1 THERAPEUTIC APPLICATIONS OF PULMONARY DELIVERY 74
4.4.1.1 Application of pulmonary delivery for non-respiratory therapies is a growing opportunity 74
4.4.2 METERED DOSE INHALERS (MDI) 77
4.4.3 DRY POWDER INHALERS (DPI) 78
4.4.4 NEBULIZERS 80
4.5 TRANSDERMAL DRUG DELIVERY 81
4.5.1 PASSIVE TRANSDERMAL DRUG DELIVERY 83
4.5.1.1 Matrix system 85
4.5.1.2 Reservoir system 86
4.5.2 ACTIVE TRANSDERMAL DRUG DELIVERY 86
4.5.2.1 Microporation 88
4.5.2.2 Iontophoresis 89
4.5.2.3 Others 90
4.6 INJECTABLE DRUG DELIVERY 91
4.6.1 INJECTABLE DRUG DELIVERY MARKET WITNESSING DEVELOPMENTS RELATED TO PRODUCT IMPROVEMENT 91
4.6.2 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES 93
4.6.2.1 Low manufacturing cost and affordable prices: key driver for conventional injection devices 94
4.6.2.2 Fillable 96
4.6.2.3 Prefilled 97
4.6.3 SELF-INJECTION DEVICES 98
4.6.3.1 Self-injection devices reduce overall treatment cost 98
4.6.3.2 Pen injectors 100
4.6.3.3 Needle-free injectors 101
4.6.3.4 Auto injectors 102
4.6.4 OTHERS 102
4.7 OCULAR DRUG DELIVERY 104
4.7.1 EYE DROPS 106
4.7.2 OINTMENTS AND GELS 108
4.7.3 OTHERS 109
4.8 NASAL DRUG DELIVERY 111
4.8.1 NASAL DRUG DELIVERY PREFERRED FOR LOCALLY ACTING DRUGS AND DELIVERY OF VACCINES 111
4.8.2 NASAL SPRAYS 113
4.8.3 NASAL INHALERS 115
4.8.4 NASAL DROPS 116
4.8.5 OTHERS 117
4.9 TOPICAL DRUG DELIVERY 118
4.9.1 TOPICAL DELIVERY MAJORLY ADOPTED FOR DERMATOLOGY DRUGS 118
4.9.2 SEMI-SOLID FORMULATIONS 121
4.9.3 LIQUID FORMULATIONS 123
4.9.4 SOLID FORMULATIONS 124
4.10 IMPLANTABLE DRUG DELIVERY 126
4.10.1 DRUG- ELUTING STENTS 129
4.10.2 IMPLANTABLE INFUSION PUMPS 131
4.10.2.1 Implantable infusion pumps largely used for therapies of chronic ailments 131
4.10.3 CONTRACEPTIVE IMPLANTS 132
4.10.4 INTRAVITREAL IMPLANTS 133
4.10.5 BRACHYTHERAPY SEEDS 135
4.11 TRANSMUCOSAL DRUG DELIVERY 137
4.11.1 ORAL (BUCCAL AND SUBLINGUAL) 140
4.11.2 OTHERS (RECTAL, VAGINAL) 141

5 GEOGRAPHIC ANALYSIS 143

5.1 INTRODUCTION 144
5.2 NORTH AMERICA 146
5.2.1 HEALTHCARE REFORMS IN THE U.S. WILL IMPACT THE DRUG DELIVERY MARKET 146
5.3 EUROPE 157
5.4 ASIA 168
5.4.1 BOOMING PHARMACEUTICAL INDUSTRY SET TO ACCELERATE THE GROWTH 168
5.5 REST OF THE WORLD (ROW) 179

6 COMPETITIVE LANDSCAPE 190

6.1 INTRODUCTION 190
6.2 MERGERS & ACQUISITIONS 191
6.3 AGREEMENTS, COLLABORATIONS, JOINT VENTURES & PARTNERSHIPS 194
6.4 NEW PRODUCT LAUNCH 196
6.5 OTHER DEVELOPMENTS 199

7 COMPANY PROFILES 209

7.1 3M COMPANY 209
7.2 ALKERMES, INC. 216
7.3 APTALIS PHARMA, INC. 222
7.4 BAXTER INTERNATIONAL, INC. 227
7.5 BECTON, DICKINSON AND COMPANY 233
7.6 CATALENT PHARMA SOLUTIONS 240
7.7 CIMA LABS 247
7.8 DALI MEDICAL DEVICES 253
7.9 ENDO HEALTH SOLUTIONS, INC. 256
7.10 FOAMIX 262
7.11 JOHNSON & JOHNSON, INC. 265
7.12 NEKTAR THERAPEUTICS, INC. 272
7.13 OPTINOSE AS 276
7.14 PSIVIDA CORPORATION 280
7.15 SKYEPHARMA PLC 285
7.16 TAPEMARK 290
7.17 THE DOW CHEMICAL COMPANY 293
7.18 VALEANT PHARMACEUTICALS 299
7.19 YPSOMED HOLDING AG 309

LIST OF TABLES

TABLE 1 GLOBAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($BILLION) 30
TABLE 2 KEY DRUG DELIVERY TECHNOLOGY PROVIDERS & MARKETER COMPANIES 59
TABLE 3 GLOBAL ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 – 2017 ($BILLION) 66
TABLE 4 ORAL DRUG DELIVERY MARKET, BY GEOGRAPHY,
2010 – 2017 ($BILLION) 67
TABLE 5 CONTROLLED RELEASE DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION) 69
TABLE 6 ODT & TASTE-MASKING MARKET, BY GEOGRAPHY,
2010 – 2017 ($BILLION) 71
TABLE 7 OTHER ORAL DRUG DELIVERY TECHNOLOGIES MARKET,
BY GEOGRAPHY, 2010 – 2017 ($BILLION) 72
TABLE 8 GLOBAL PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE,
2010 – 2017 ($BILLION) 75
TABLE 9 PULMONARY DRUG DELIVERY MARKET, BY GEOGRAPHY,
2010 – 2017 ($BILLION) 76
TABLE 10 COMPARATIVE OVERVIEW OF PULMONARY DRUG DELIVERY DEVICES 76
TABLE 11 METERED DOSE INHALATION MARKET, BY GEOGRAPHY,
2010 – 2017 ($BILLION) 78
TABLE 12 DRY POWDER INHALATION MARKET, BY GEOGRAPHY,
2010 – 2017 ($BILLION) 79
TABLE 13 NEBULIZERS MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION) 80
TABLE 14 GLOBAL TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 – 2017 ($BILLION) 82
TABLE 15 TRANSDERMAL DRUG DELIVERY MARKET, BY GEOGRAPHY,
2010 – 2017 ($BILLION) 83
TABLE 16 PASSIVE TRANSDERMAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2010 – 2017 ($BILLION) 84
TABLE 17 PASSIVE TRANSDERMAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION) 85
TABLE 18 ACTIVE TRANSDERMAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION) 87
TABLE 19 ACTIVE TRANSDERMAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 88
TABLE 20 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2010 – 2017 ($BILLION) 92
TABLE 21 INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY,
2010 – 2017 ($BILLION) 93
TABLE 22 CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,
2010 – 2017 ($BILLION) 95
TABLE 23 CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY,
2010 – 2017 ($BILLION) 96
TABLE 24 GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCT,
2010 – 2017 ($MILLION) 98
TABLE 25 SELF-INJECTION DEVICES MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 99
TABLE 26 OTHER INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 103
TABLE 27 GLOBAL OCULAR DRUG DELIVERY MARKET, BY FORMULATION,
2010 – 2017 ($BILLION) 105
TABLE 28 OCULAR DRUG DELIVERY MARKET, BY GEOGRAPHY,
2010 – 2017 ($BILLION) 106
TABLE 29 EYE DROP DRUG DELIVERY MARKET, BY GEOGRAPHY,
2010 – 2017 ($BILLION) 107
TABLE 30 OINTMENT & GEL DELIVERY MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 109
TABLE 31 OTHER OCULAR DRUG DELIVERY MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 110
TABLE 32 GLOBAL NASAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 – 2017 ($BILLION) 112
TABLE 33 NASAL DRUG DELIVERY MARKET, BY GEOGRAPHY,
2010 – 2017 ($BILLION) 113
TABLE 34 NASAL SPRAY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION) 114
TABLE 35 NASAL INHALER MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 115
TABLE 36 NASAL DROPS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 116
TABLE 37 OTHER NASAL DELIVERY FORMULATIONS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 117
TABLE 38 GLOBAL TOPICAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 – 2017 ($BILLION) 120
TABLE 39 TOPICAL DRUG DELIVERY MARKET, BY GEOGRAPHY,
2010 – 2017 ($BILLION) 121
TABLE 40 SEMI-SOLID TOPICAL FORMULATION MARKET, BY GEOGRAPHY,
2010 – 2017 ($BILLION) 122
TABLE 41 LIQUID TOPICAL FORMULATION MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 124
TABLE 42 SOLID TOPICAL FORMULATION MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 125
TABLE 43 GLOBAL IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE,
2010 – 2017 ($BILLION) 127
TABLE 44 IMPLANTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY,
2010 – 2017 ($BILLION) 128
TABLE 45 DRUG-ELUTING STENTS MARKET, BY GEOGRAPHY,
2010 – 2017 ($BILLION) 130
TABLE 46 IMPLANTABLE INFUSION PUMPS MARKET, BY GEOGRAPHY,
2010 – 2017 ($BILLION) 132
TABLE 47 CONTRACEPTIVE IMPLANTS MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 133
TABLE 48 INTRAVITREAL IMPLANTS MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 134
TABLE 49 BRACHYTHERAPY SEEDS MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 136
TABLE 50 GLOBAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 – 2017 ($BILLION) 138
TABLE 51 GLOBAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION) 139
TABLE 52 ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY GEOGRAPHY,
2010 – 2017 ($BILLION) 141
TABLE 53 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES MARKET,
BY GEOGRAPHY, 2010 – 2017 ($MILLION) 142
TABLE 54 DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION) 145
TABLE 55 NORTH AMERICA: DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($BILLION) 147
TABLE 56 NORTH AMERICA: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($BILLION) 148
TABLE 57 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($BILLION) 149
TABLE 58 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 – 2017 ($BILLION) 150
TABLE 59 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET,
BY TECHNOLOGY, 2010 – 2017 ($BILLION) 151
TABLE 60 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET,
BY FORMULATION, 2010 – 2017 ($BILLION) 152
TABLE 61 NORTH AMERICA: NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($BILLION) 153
TABLE 62 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET,
BY FORMULATION, 2010 – 2017 ($MILLION) 154
TABLE 63 NORTH AMERICA: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($MILLION) 155
TABLE 64 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET,
BY MUCOSA TYPE, 2010 – 2017 ($MILLION) 156
TABLE 65 EUROPE: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($BILLION) 158
TABLE 66 EUROPE: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 – 2017 ($BILLION) 159
TABLE 67 EUROPE: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE,
2010 – 2017 ($BILLION) 160
TABLE 68 EUROPE: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 – 2017 ($BILLION) 161
TABLE 69 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION) 162
TABLE 70 EUROPE: OCULAR DRUG DELIVERY MARKET, BY FORMULATION,
2010 – 2017 ($MILLION) 163
TABLE 71 EUROPE: NASAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 – 2017 ($MILLION) 164
TABLE 72 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 – 2017 ($MILLION) 165
TABLE 73 EUROPE: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($MILLION) 166
TABLE 74 EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 – 2017 ($MILLION) 167
TABLE 75 ASIA: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($BILLION) 169
TABLE 76 ASIA: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 – 2017 ($BILLION) 170
TABLE 77 ASIA: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE,
2010 – 2017 ($BILLION) 171
TABLE 78 ASIA: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 – 2017 ($BILLION) 172
TABLE 79 ASIA: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 – 2017 ($MILLION) 173
TABLE 80 ASIA: OCULAR DRUG DELIVERY MARKET, BY FORMULATION,
2010 – 2017 ($MILLION) 174
TABLE 81 ASIA: NASAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 – 2017 ($MILLION) 175
TABLE 82 ASIA: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 – 2017 ($MILLION) 176
TABLE 83 ASIA: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE,
2010 – 2017 ($MILLION) 177
TABLE 84 ASIA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 – 2017 ($MILLION) 178
TABLE 85 ROW: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($BILLION) 180
TABLE 86 ROW: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 – 2017 ($BILLION) 181
TABLE 87 ROW: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE,
2010 – 2017 ($BILLION) 182
TABLE 88 ROW: TRANSDERMAL DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 – 2017 ($MILLION) 183
TABLE 89 ROW: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 – 2017 ($MILLION) 184
TABLE 90 ROW: OCULAR DRUG DELIVERY MARKET, BY FORMULATION,
2010 – 2017 ($MILLION) 185
TABLE 91 ROW: NASAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 – 2017 ($MILLION) 186
TABLE 92 ROW: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 – 2017 ($MILLION) 187
TABLE 93 ROW: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE,
2010 – 2017 ($MILLION) 188
TABLE 94 ROW: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 – 2017 ($MILLION) 189
TABLE 95 MERGERS & ACQUISITIONS, 2011 –2013 191
TABLE 96 AGREEMENTS, COLLABORATIONS, JOINT VENTURES & PARTNERSHIPS, 2011 –2013 194
TABLE 97 NEW PRODUCT LAUNCH, 2010 – 2012 197
TABLE 98 OTHER DEVELOPMENTS, 2010 – 2013 200
TABLE 99 3M COMPANY: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 211
TABLE 100 3M COMPANY: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 212
TABLE 101 ALKERMES: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 218
TABLE 102 BAXTER INTERNATIONAL: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 229
TABLE 103 BAXTER INTERNATIONAL: MEDICAL PRODUCTS TOTAL REVENUE,
2010 – 2012($MILLION) 229
TABLE 104 BAXTER INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 230
TABLE 105 BECTON, DICKINSON: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 234
TABLE 106 BECTON, DICKINSON: MEDICAL DIVISION TOTAL REVENUE,
BY SEGMENT, 2010 – 2012 ($MILLION) 235
TABLE 107 BECTON, DICKINSON: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012($MILLION) 235
TABLE 108 CATALENT PHARMA SOLUTIONS: TOTAL REVENUE, BY SEGMENT,
2009 – 2011 ($MILLION) 241
TABLE 109 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE,
BY SEGMENT, 2010 – 2012 ($MILLION) 249
TABLE 110 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE,
BY GEOGRAPHY, 2010 – 2012 ($MILLION) 250
TABLE 111 ENDO HEALTH SOLUTIONS, INC.: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 258
TABLE 112 JOHNSON & JOHNSON, INC.: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 267
TABLE 113 JOHNSON & JOHNSON, INC.: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 267
TABLE 114 THE DOW CHEMICAL COMPANY: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 294
TABLE 115 VALEANT PHARMACEUTICALS: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 300
TABLE 116 YPSOMED: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 310
TABLE 117 YPSOMED: TOTAL REVENUE, BY GEOGRAPHY, 2009 ($MILLION) 311
TABLE 118 YPSOMED: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2011 ($MILLION) 311

LIST OF FIGURES

FIGURE 1 GLOBAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION (2012) 31
FIGURE 2 DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION) 32
FIGURE 3 GLOBAL DRUG DELIVERY MARKET SEGMENTATION 35
FIGURE 4 MARKET DYNAMICS 38
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS FOR DRUG DELIVERY MARKET 49
FIGURE 6 VALUE CHAIN ANALYSIS 51
FIGURE 7 GLOBAL PULMONARY DRUG DELIVERY: MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2012 53
FIGURE 8 GLOBAL TRANSDERMAL DRUG DELIVERY: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012 54
FIGURE 9 GLOBAL CONVENTIONAL INJECTION DEVICES: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012 55
FIGURE 10 GLOBAL SELF-INJECTION DEVICES: MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2012 57
FIGURE 11 GLOBAL IMPLANTABLE DRUG DELIVERY: MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2012 58
FIGURE 12 OPPORTUNITY MATRIX: GLOBAL DRUG DELIVERY MARKET (2012) 63
FIGURE 13 ORAL DRUG DELIVERY MARKET SHARE (2012) 66
FIGURE 14 KEY GROWTH STRATEGIES, 2010 – 2013 190
FIGURE 15 3M COMPANY: TOTAL REVENUE AND R&D EXPENSES,
2009 – 2011 ($MILLION) 210
FIGURE 16 ALKERMES: TOTAL REVENUE AND R&D EXPENDITURE,
2009 – 2011 ($MILLION) 217
FIGURE 17 APTALIS PHARMA, INC.: TOTAL REVENUE AND R&D EXPENSES,
2009 – 2011 ($MILLION) 223
FIGURE 18 BAXTER INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES,
2010 – 2012 ($MILLION) 228
FIGURE 19 BECTON, DICKINSON: TOTAL REVENUE AND R&D EXPENDITURE,
2010 – 2012 ($MILLION) 234
FIGURE 20 CATALENT PHARMA SOLUTIONS: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION) 241
FIGURE 21 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION) 248
FIGURE 22 ENDO HEALTH SOLUTIONS, INC.: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION) 257
FIGURE 23 JOHNSON & JOHNSON, INC.: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION) 266
FIGURE 24 NEKTAR THERAPEUTICS, INC.: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION) 273
FIGURE 25 PSIVIDA CORPORATION: TOTAL REVENUE, 2009 – 2011 ($MILLION) 281
FIGURE 26 SKYEPHARMA PLC: TOTAL REVENUE AND R&D EXPENSES,
2009 – 2011 ($MILLION) 286
FIGURE 27 THE DOW CHEMICAL COMPANY: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION) 294
FIGURE 28 VALEANT PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION) 300
FIGURE 29 YPSOMED: TOTAL REVENUE AND R&D EXPENSES,
2009 – 2011 ($MILLION) 310